Cleveland BioLabs to Present at Roth Capital Partners Growth Stock Conference
August 31 2006 - 1:36PM
PR Newswire (US)
CLEVELAND, Aug. 31 /PRNewswire-FirstCall/ -- Cleveland BioLabs,
Inc. (Nasdaq: CBLI; Boston Stock Exchange: CFB), today announced
that the company is scheduled to present at the Roth Capital
Partners New York Growth Stock Conference to be held September 7-8.
Michael Fonstein, Ph.D., President and Chief Executive Officer at
Cleveland BioLabs, will give a presentation on the company followed
by a question and answer session on September 7, at 12:00 p.m. ET.
The presentation will be broadcast live over the Internet.
Interested parties may tune in to the live presentation by visiting
the company's website at: http://www.cbiolabs.com/ or alternatively
http://www.wsw.com/webcast/roth8/cbli/. Cleveland BioLabs currently
has two lead compounds in late stages of development. Curaxin
CBLC102 is a small molecule designed to kill tumor cells by
simultaneously targeting two key regulators of apoptosis. The
Company has received approval to initiate Phase II trials with
CBLC102 in hormone refractory prostate cancer. The Company's other
lead compound, CBLB502, is a modified protein of a microbe that
protects cells from apoptosis. It has shown efficacy in protection
against lethal doses of radiation in rodents and non-human primates
and is on an accelerated approval pathway for the treatment of
acute radiation syndrome, which results from exposure to high
levels of radiation following a nuclear or radiological incident.
Other applications for this technology include protection from
cancer treatment side effects. About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
with the goal to identify and develop new types of drugs for the
protection of normal tissues from exposure to radiation and other
stresses and for cancer treatment. Our development efforts are
based on discoveries made in connection with the investigation of
the cell-level process known as apoptosis. To learn more about
Cleveland BioLabs Inc., please visit the company's website at
http://www.cbiolabs.com/. This press release contains
forward-looking statements that reflect our current view with
respect to various aspects of the events described above. Actual
results could be significantly different. Factors that could affect
results include those set forth in filings made by Cleveland
BioLabs, Inc. with the Securities and Exchange Commission. These
factors include, but are not limited to, those discussed in our
Registration Statement on Form SB-2 under the caption "Risk
Factors." We caution readers not to place undue reliance on these
forward-looking statements. Although forward-looking statements
help provide complete information about future prospects, readers
should keep in mind that forward- looking statements are much less
reliable than historical information. DATASOURCE: Cleveland
BioLabs, Inc. CONTACT: Rachel Levine of The Global Consulting
Group, +1-646-284-9439, Web site: http://www.cbiolabs.com/
Copyright